My concern, as you know, is that the human H1N1 that's circulating regularly is resistant to Tamiflu, and a lot of it is perhaps even resistant to Relenza. Where is the money coming from for the research for new antivirals? A real strategy would be trying to get ahead of the curve. Are we able, with cuts to CIHR, with cuts to everywhere we know, to have a national antiviral strategy that will give us what we need should this new and more severe virus in the fall end up resistant to the two drugs we already have?
